Management and Care – The Changing Landscape of Multiple Sclerosis

In early June 2008, the 18th meeting of the European Neurological Society (ENS) welcomed over 3,000 neurologists and physicians from all over the world to Nice, France. Among the multitude of symposia, oral sessions and scientific programmes on the latest in the progress made in neurodegenerative diseases were presentations by leaders in the field of multiple sclerosis (MS). Noted key points discussed included new developments in research, and the concept that drug efficacy varies depending on the treatment stage: beginning treatment earlier in the course of the disease may be more beneficial. With strong evidence presented in support of initiating treatment earlier, neurologists have been offered the opportunity to protect patients against disease progression. By implementing early intervention it may be possible to improve the prognosis of this debilitating neurodegenerative disease.

Latest Developments in Multiple Sclerosis

In a symposium discussing autoimmune disorders of the nervous system, Professor Giancarlo Comi (Italy) addressed important new issues arising from recent MS research on disease prevalence, causal factors, disease evolution and MS therapy. Recent epidemiological studies have suggested an increase in the prevalence of MS in a number of European nations – Spain, France, Greece, Germany and Italy – particularly in the last five years. There is a trend for a nearly exclusive increase of the disease in women compared with men, says Professor Comi, attributed to lifestyle changes in women or improvements in hygiene and control of early childhood infections.

The role of genetics and environment as causal factors of MS continues to be debated. The genome-wide approach has identified interleukin-7 receptor alpha (IL-7 rα) and interleukin-2 receptor alpha (IL-2 rα) alleles as risk factors for developing MS. There is also evidence of an association between developing MS and low exposure to sunlight and vitamin D, and much research is being conducted on the relationship between MS and Epstein-Barr virus (EBV) and, more recently, varicella zoster virus (VZV). EBV RNA and EBV antigens have been detected in a high proportion of brain tissue samples from MS patients, indicative of a role for EBV in MS immunopathology. There is also evidence of a very strong correlation between the viral load of VZV in cerebrospinal fluid (CSF) and blood samples and the appearance of an MS attack.

Other research has focused on the mechanisms concerning the irreversible damage to the central nervous system (CNS) during disease progression. Not only can axonal damage and inflammation in early phases of the disease produce acute lesions, but it appears that initial damage can also increase damage in positive feedback loops through the overexpression of glutamate receptors, voltage-gated sodium channel (Nav)1.6 and calcium channels. The extent of focal atrophy around a lesion has been associated with brain atrophy and loss of volume. Other factors such as the duration of the inflammation, the size of the lesion and the location of the lesion have been linked to predicting the degree of persistent damage. Furthermore, lesion damage has been found to evolve continuously in all phases of the disease in as little as a 12-month follow-up. With such detrimental effects on the brains of MS patients, Professor Comi concluded this presentation with a call to improve treatment by increasing accessibility to new treatments and improving the ability to better apply existing therapies.

Optimising Therapy Through Earlier Treatment and Drug Selection in Different Phases of the Disease

A theme common to many of the MS presentations at the ENS was to initiate MS therapy at an earlier stage, not just when a clinically definitive diagnosis has been made. Many clinical trials have shown a dissociation between disease progression and inflammation, supporting the hypothesis that MS is primarily an inflammatory disorder and that inflammatory axonal injury underlies the formation of new lesions and axonal degeneration. By protecting against inflammation, it may then be possible to slow progression in MS, and in turn reduce the degree of tissue injury and degeneration of the nervous system. According to Professor Alistair Compston (UK) in his talk about the rationale for early treatment, offering immunological therapies early in the course of the disease – before the cascade of events leading to axonal degeneration is irreversibly established – may be most beneficial in preventing sustained disability and disease progression. Indeed, early treatment has been shown to limit axonal damage and protect against irreversible nervous damage and ensuing disability.

Treatment After a Clinically Isolated Syndrome

Patients who have experienced a clinically isolated syndrome (CIS) are at high risk of developing clinically definite MS (CDMS). Epidemiological studies and clinical trials have shown that approximately 85% of CIS patients are diagnosed with MS within two years. It is at this early stage of the disease that treatment should be initiated, elaborated Professor Comi, with evidence from magnetic resonance imaging (MRI) studies showing brain atrophy and decreased brain volume in the very early stages of MS.

All three clinical trials testing the use of interferon beta formulations in CIS patients – the Betaferon/Betaseron in Newly Emerging Multiple Sclerosis For Initial Treatment (BENEFIT) study, the Controlled High-risk Avonex Multiple Sclerosis Prevention study (CHAMPS) study and the Early Treatment Of MS (ETOMS) study – have shown obvious advantages with early therapy, including a reduced rate of conversion
Improving Patient Outcome Through Earlier Treatment

In her presentation entitled ‘Earlier is better – the importance of MS treatment’, Dr Mar Tintoré (Spain) explained that a first neurological event warrants early treatment because of the events that occur early in the disease course. Early axonal damage is correlated to inflammation and may be irreversible, and atrophy appears soon after the occurrence of a clinically isolated syndrome (CIS). Early factors have a significant impact in the long term; evidence from natural history studies negatively correlates the number of attacks in the early years of the disease with the time it takes to reach greater disability and disease severity, and the time interval between the first and second attacks has proved to be a major clinical factor in predicting long-term disability. Magnetic resonance imaging (MRI) parameters have also proved useful in assessing the risk of multiple sclerosis (MS) disease progression; CIS patients followed for a median of seven years showed that those who developed new T2 lesions faced an increased risk of progressing to clinically definite MS (CDMS). Furthermore, increases in lesion volume are correlated with greater long-term disability. Indeed, the CHAMPS and PreCISE studies in monofocal patients and the ETOMS and BENEFIT studies in mono- and multifocal patients have all shown that early treatment can significantly delay the development to CDMS compared with placebo (see Figure 1).

Another important message raised in recent years is that drug efficacy may vary depending on the disease phase. In the CIS stage, drug efficacy is around 50%, but drops to 30% for patients in the relapsing–remitting phase and continues to decrease through the disease course (see Figure 2). This key concept has been seen with a number of different drugs, says Dr Tintoré, with the same drug having greater efficacy when introduced earlier. If physicians delay in treating patients, then not only are patients at greater risk of earlier disease progression and disability, but when they finally receive disease-modifying therapies they will experience much less efficacy.

A similar emphasis on early treatment was expressed by Professor David Bates (UK). Initial inflammation of the nervous system occurs early in the disease, leading to demyelination and subsequent axonal loss. This inflammation may occur in a pre-clinical way, where it is unnoticed until a patient experiences a clearly eloquent attack. Throughout the disease, a majority of patients will experience a gradual loss of brain tissue and continued and increasing damage to the axons, with progressive deterioration in cognition and memory, all the while showing a gradual increase in damage on the MRI scan (see Figure 3). Because the available MS treatments are predominantly anti-inflammatory, it follows that their greatest effect will take place at the beginning of the disease course when the nervous system is inflamed. Although the available
to CDMS (see Table 1), prolonged time to a second attack and reduced brain MRI activity. Furthermore, extensions of these studies with at least three years of follow-up confirm that CIS patients who received early therapy continued to benefit significantly in terms of preventing a second attack. The BENEFIT trial revealed that even as little as three years of early treatment can significantly reduce the risk (by 40%) of confirmed expanded disability status scale (EDSS) progression compared with patients in whom treatment with interferon beta-1b (Betaferon, Bayer Schering Pharma) was delayed. Furthermore, the prospectively planned follow-up study showed that after three years of this early treatment conferred an advantage in cognitive function over patients who received delayed treatment (p=0.011), as scored by the Paced Auditory Serial Addition Test (PASAT), which measures intellectual function and cognition. A retrospective follow-up of
CHAMPS (the Controlled High Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance [CHAMPIONS Study]) after five years found that early treatment with interferon beta-1a could significantly lower the cumulative probability of developing CDMS compared with delayed treatment.30 The results of the Study to Evaluate the Efficacy of Early Glatiramer Acetate in Delaying the Conversion to CDMS of Subjects Presenting With a Clinically Isolated Syndrome (PreCiSe), presented in a separate session by Professors Comi and Massimo Filippi on behalf of the PreCiSe study group, showed that compared with placebo, glatiramer acetate (Copaxone, Teva Pharmaceutical) reduced the risk of developing CDMS by 45%.31 Interferon beta-1a has also shown clinical and cognitive benefits for patients with early relapsing–remitting MS (RRMS) in the Cognition Impairment in Multiple Sclerosis (COGIMUS) study at two and three years, respectively.32 Furthermore, evidence from a Cochrane meta-analysis supports the idea of early treatment; interferon beta therapy applied early – at the time of the first episode suggestive of MS – showed significant ability in preventing the conversion from CIS to CDMS in all studies analysed, with benefits persisting through two years of treatment.33

So, should all patients with a CIS be treated immediately following the first neurological episode? Not necessarily, says Professor Comi, as it depends largely on the patient’s clinical presentation. Rather, the following prognostic factors – as determined from ETOMS, CHAMPS, BENEFIT and PreCiSe – can help to predict which CIS patients are at increased risk of early conversion to CDMS:

- ≥9 T2 lesions;
- >1 gadolinium-enhancing (Gd+) lesion;
- multifocal presentation;
- higher clinically and MRI-measured disease severity at onset, with a longer pre-clinical phase and/or more aggressive disease course; and
- ongoing brain activity in the MRI indicative of inflammation.

According to Professor Comi’s personal recommendations for patients with a first attack and brain MRI suggestive of MS, early treatment should be initiated for those exhibiting one or more negative prognostic factor, whereas those lacking negative prognostic factors should be carefully monitored and given repeat MRIs, with therapy being initiated on evidence of temporal dissemination. Patients who have suffered an attack but retain otherwise normal brain MRI or an MRI scan atypical of MS are at low risk of conversion to CDMS or disability, and should undergo annual MRI scans.34 However, Professor Comi does stress that he disagrees with the generalisation that CIS patients should not be treated with immunomodulatory drugs because of the chance that a subgroup may have a benign disease course. The reason for this is that the purpose of treating CIS patients is to anticipate and prevent potential damage; this is essential – and the earlier, the better.

Although it may prove useful to follow official guidelines such as those provided by the European Federation of Neurological Societies, the patient’s disease phase must also be assessed as the initial step in selecting a treatment, accounting primarily for the clinical activity, with MRI activity as secondary criterion. It is known that the currently available treatments of interferon beta and glatiramer acetate can improve patient outcome by reducing the rates of relapse frequency and MRI activity. However, long-term efficacy in delaying disability remains uncertain. Drawing on the data from the head-to-head comparisons Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND),35 Rebif vs Glatiramer Acetate in Relapsing MS Disease (REGARD)36 and Betaseron vs Copaxone in MS with Triple-Dose Gadolinium and 3-T MRI Endpoints (BECOME),37 Professor Confavreux concluded that the similarities in efficacy and long-term safety exhibited by the interferon betas and glatiramer acetate qualifies them as prime candidates in the first-line treatment of active forms of RRMS.

The efficacy of natalizumab is even greater, with a 68% reduction in relapse rate and 83% reduction of new or enlarging T2 lesions,38 but it is indicated as a second-line therapy for RRMS patients who have failed treatment with interferon beta or glatiramer acetate, or for treatment-naive patients with rapidly evolving severe MS.40 However, the association with serious and fatal infection such as progressive multifocal leukoencephalopathy (PML) and possible neoplastic complications requires close monitoring upon prescribing natalizumab. Immunosuppressive third-line therapies such as mitoxantrone or cyclophosphamide are recommended for severe aggressive MS or disease breakthrough.

Deciding on a treatment is rarely as simple and clear-cut as following recommendations, however; MS is a long-term, chronic and very heterogeneous disease, with disease activation presenting differently between patients. Patient characteristics, such as age at onset and apparent disease severity, and clinical factors, such as drug efficacy, safety and tolerability, need to be considered together in assessing treatment options; ultimately, any chosen therapy should have an extremely important effect on the disease pattern and future prognosis of MS.

Table 1: Risk Reduction for Progression to Clinically Definite Multiple Sclerosis

<table>
<thead>
<tr>
<th>Studies in Multi- and Monofocal Patients</th>
<th>n</th>
<th>Risk Reduction (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENEFIT</td>
<td>468</td>
<td>50</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ETOMS</td>
<td>309</td>
<td>35</td>
<td>0.045</td>
</tr>
<tr>
<td>Monofocal patients only</td>
<td>n</td>
<td>Risk Reduction (%)</td>
<td>p-value</td>
</tr>
<tr>
<td>CHAMPS</td>
<td>383</td>
<td>44</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>PRECISE</td>
<td>481</td>
<td>45</td>
<td>0.0005</td>
</tr>
</tbody>
</table>


Management and Care – The Changing Landscape of Multiple Sclerosis

Induction Therapy in Multiple Sclerosis

There are cases where patients continue to experience frequent relapses and disease progression despite disease-modifying therapy. Combination therapy is typically designated for treatment failures, and
**Benign versus Non-benign MS – Is Disability Only a Factor of Time?**

As a proponent of early treatment, Dr Mar Tintoré spoke of the problems in diagnosing patients as having benign multiple sclerosis (MS). In a longitudinal study, 48% of patients initially classified as benign by their neurologists 10 years after disease onset were found to be non-benign after a further 10 years of follow-up, progressing from expanded disability status scale (EDSS) <3.0 to EDSS ≥3.0. Furthermore, nearly half of patients considered benign have exhibited cognitive impairment. Benign MS may therefore become non-benign MS over time.

Illustrating an even more dramatic impact, Professor Bernd Kieseier (Germany) addressed a study where out of 47 benign patients followed up for 21 years, 18 had died, 22 had become disabled and only seven had remained benign. The authors of this study concluded that classifying patients as benign after 10 years of EDSS ≥3.0 has poor predictive value. Professor Kieseier adamantly expressed that there is no way to predict whether a patient has benign MS, and that in his opinion there may not even truly be a benign condition: if the brains of MS patients and those of unafflicted individuals were compared, inflammation and cell damage would still be found regardless. Given that MS is a chronic disease with ongoing inflammation, there is an urgency to treat these patients as early as possible.

Similar to the problem of identifying which patients qualify for early MS treatment, those with suboptimal responses also need to be identified for treatment, be it by switching between immunomodulatory agents or switching from immunomodulation to immunosuppression; so far, clinical criteria, MRI criteria and biomarkers have been the most help in selecting patients for induction therapy. Dr Lisak concluded that a composite using criteria indicative of highly active disease that clearly warrants induction with immunosuppressive therapy is necessary, and presented provisional recommendations put together by himself and his colleague Dr Omar Khan (US). These recommendations state that observing any three or more of the following criteria in a patient should compel the clinician to initiate immunosuppressive therapy:

- >2 relapses in the past 12 months requiring corticosteroid treatment;
- recurrent brain stem or spinal cord relapses;
- EDSS >3.0 within three to six months following the last relapse;
- ≥3 Gd+ lesions that are >3mm in size on a single scan;
- ≥3 new T2 lesions in the past 12 months; and
- any evidence of atrophy.

**Diagnosing Benign Multiple Sclerosis**

Designating a case of MS as benign confers a favourable course of MS in which such patients experience mild or no disability after the initial clinical onset. However, an increasing amount of emerging data has instigated great debate as to how benign MS can be diagnosed with absolute certainty, and whether or not such a condition actually exists. The problem with this label is that patients with benign MS are under the impression that their symptoms will not worsen, and as a result will be unlikely to seek out the same level of medical attention as patients who have been diagnosed with CDMS. Moreover, for benign patients who become non-benign over time, this poses a great loss in terms of health and protection against disability that could otherwise have been prolonged or delayed with early treatment.

Patients with benign MS experience fewer lesions than patients with early RRMS. However, lesion load has been found to be higher in benign patients than those with early RRMS and those with non-disabling RRMS. Furthermore, no significant difference could be found in normal brain volume and, by association, neuroaxonal brain viability between benign and early RRMS patients. The researchers of these studies argue that patients with benign MS experience a relative sparing of cortical damage, which then bestows upon them favourable clinical disease courses, but the presence of lesions in benign patients and the fact that these patients have an increase in lesion loads cannot be ignored. Cognitive dysfunction in benign MS is also associated with significantly more severe damage to the corpus callosum, with significantly higher lesion load compared with benign patients without cognitive impairment.

**Updates on Efficacy in Recommended Multiple Sclerosis Therapies**

Prior to prescribing any sort of treatment to a patient, drug efficacy, safety and tolerability are all factors that must be carefully considered. This section of the report will focus on the advances and recent research that have been made available in these areas, as discussed at the ENS, as well as a special focus on the up-and-coming drugs in development.

Conclusive comparisons between the various therapies available for MS have been rather difficult because to date there has been no single study...
With three years of the planned five-year follow-up to the BENEFIT study completed, data show that there are indeed advantages for early treatment with interferon beta-1b (Betaferon) following the initial demyelinating event. Presenting on the efficacy of Betaferon in early disease stages, Professor Comi indicated a greater reduction in relapse rate and risk of progression to clinically definite multiple sclerosis (CDMS) over three years with early treatment compared with delayed treatment and, as previously mentioned, a delay in the time to confirmed expanded disability status scale (EDSS) progression.28 After three years of follow-up, only 37% of patients receiving early treatment developed CDMS, a risk reduction of 41%, compared with the 51% of patients who received delayed treatment. The risk of progression to disability was also reduced by 40%, with 16% of early-treated patients diagnosed with confirmed EDSS progression compared with 24% of patients with delayed treatment. This study holds an important message: the early intervention is not just a delay in worsening conditions or a modification of the debilitating disease, but, according to Professor Comi, a demonstration that these patients are being treated for the accumulation of irreversible damage. Furthermore, the already highly significant results from BENEFIT are likely understated since a majority of the delayed-treatment arm received at least one year of interferon beta-1b as well. The five-year follow-up study is set to be completed in 2008, and the BENEFIT project has been extended to analyse various outcomes, including time to CDMS and MS according to the McDonald criteria, disability, quality of life, magnetic resonance imaging (MRI) measures and adherence.

As part of the symposium ‘Targeting the pathophysiology of MS: transforming discovery into care’, Dr Kieseier spoke about the importance of initiating treatment at diagnosis, in which a ‘window of opportunity’ exists to offer neurologists the chance to possibly maintain an isolated syndrome and avoid future progression to secondary progression or chronic illness (see Figure 4). All patients in the CHAMPS study received interferon beta-1a intramuscularly, but those randomised to receive immediate treatment from study onset rather than placebo and delayed interferon beta-1a experienced greater benefits with reduced risk of progression to CDMS and annualised relapse rate over five years.27,30 Additionally, interferon beta-1a has been shown to decrease the mean number of MRI lesions, brain atrophy and cognitive dysfunction.53 Dr Kieseier noted that patients who receive delayed treatment never catch up with those receiving early treatment in terms of experiencing the same benefits.

The next speaker in this symposium, Dr Norman Putzki (Germany), presented an argument supporting the role of natalizumab as an anti-inflammatory drug in MS. With the drug indicated for patients with more active disease, a sub-analysis of highly active patients who were placebo-treated in the AFFIRM trial showed that natalizumab retained similar efficacy in active disease to that seen in patients who received natalizumab earlier, and in so doing was able to reduce the annualised relapse rate of these highly active patients. Risk reduction of disease progression over two years decreased by more than 50%, and this effect was observed in highly active patients as well.29 Crucial to demonstrating the relative difference between receiving and not receiving treatment, according to Dr Putzki, is the fact that natalizumab increased the proportion of patients free of clinical or MRI disease activity by five-fold, regardless of baseline severity.82

Cases of progressive multifocal leukoencephalopathy (PML) have previously been reported for natalizumab/interferon beta-1a combination therapy, which led to the temporary withdrawal of natalizumab from the market. One study suggested that the likelihood of PML over 18 months of treatment would be roughly one in 1,000 patients.83 However, since the conclusion of the ENS, two new and separate cases of PML in patients receiving natalizumab monotherapy over a span of approximately 14 and 17 months, respectively, has emerged.84 With more than 43,000 patients who have been exposed to natalizumab,85 these occurrences of PML remain in the predicted frequency of one incidence in every 1,000 patients.

Data from the BEYOND study presented at the ENS comparing the efficacy, safety and tolerability of interferon beta-1b 250mcg, interferon beta-1b 500mcg and glatiramer acetate 20mg daily in RRMS patients over a period of 24 months showed no significant differences between any of the treatment arms in relapse risk, the number or volume of T1
Multiple Sclerosis

**Improving Tolerability as a Means of Ameliorating Drug Therapy**

Presenting data from the Rebif New Formulation Study, Dr William Camus (France) spoke of the improvements in immunogenicity, safety and tolerability. The objective of the phase IIII single-arm, open-label Rebif New Formulation (RNF) Study was to evaluate the product’s safety and immunogenicity in relapsing–remitting multiple sclerosis (RRMS). Enrolment criteria required patients aged 18–60 years of age with expanded disability status scale (EDSS) <6.0 to be naïve to treatment with interferon beta. Patients self-injected RNF at 44mcg three times a week over a period of two years. Patients treated with RNF had a lower rate of neutralising antibodies compared with data from the EVIDENCE and REGARD studies, indicative of an improved immunogenical profile, and also experienced a significant reduction in annualised relapse rate.

Focusing on adverse events, there was a nearly three-fold reduction in injection-site reactions compared with previous studies, at 30.8% compared with 85.8 and 41.2% in the EVIDENCE and REGARD studies, respectively. Surprisingly, though, flu-like symptoms were much higher, at 71.5% versus 49.0 and 36.0% in the EVIDENCE and REGARD studies, respectively, which has prompted researchers to further analyse this issue through the Transition to Rebif New Formulation (TRANSFER) study.

Natalizumab has been recommended as second-line therapy for patients who continue to progress while receiving the first-line disease-modifying therapies. Patients with relapsing MS in the Natalizumab Safety and Efficacy in Relapsing Multiple Sclerosis (AFFIRM) or Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) trials were monitored for disease activity, and researchers found that natalizumab, whether as a monotherapy or in combination with interferon beta-1a, yielded a significantly higher proportion of disease-activity-free patients compared with placebo over two years based on both clinical and MRI yield. A significantly higher proportion of disease-activity-free patients was seen whether as a monotherapy or in combination with interferon beta-1a.

The BENEFIT studies have demonstrated good tolerability to interferon beta-1b in patients with CIS, with a high adherence rate after three years (>73.3%) and a large proportion (>89.3%) of patients choosing to continue therapy in the follow-up study. A comparison of tolerability between interferon beta-1b 250mcg and glatiramer acetate in the BEYOND study showed that patients treated with interferon beta-1b were more likely to experience flu-like symptoms, although the incidence of this adverse effect decreased with time. In contrast, injection-site reactions were commonly reported by patients receiving glatiramer acetate.

As with any chronic life-long disease, adherence to drug therapy is a major determinant of the success of the disease-modifying therapy, and this concept is no different in MS. Adherence and relapse rate are closely associated: one study has shown that patients who refused to adhere to treatment for over 90 days face a significantly increased risk of severe MS relapse compared with patients with shorter or no gaps in drug-treatment.

Studies have also shown that adherence varies depending on the drug in question. Adherence in the BEYOND trial was high in all groups, but a slightly higher number of patients treated with interferon beta-1b 500mcg (82%) saw the study through to completion compared with those treated with high-dose interferon beta-1b 500mcg (73%) or glatiramer acetate (78%).

Certainly, the results from clinical trials with respect to adherence are an area to be considered by physicians when prescribing medications for patients, and the subject of adherence is an important one, as drug compliance is closely linked to the patient’s quality of life – the efficacy of a drug is irrelevant if patients exhibit poor compliance, for example, due to bad adverse effects or low tolerance, which ultimately leads to disease progression and poor patient outcome. However, quality of life is not solely dependent on drug use and compliance: one study assessed a cohort of Polish subjects with MS to determine the most important factors affecting quality of life and found depression, level of disability, fatigue and marital status to be the strongest predictors of quality of life. In the
Can Adherence Be Further Ameliorated?

Presenting a comprehensive comparison of the tolerability of multiple sclerosis (MS) therapies, Dr Karl Baum (Germany) spoke about the factors affecting patient adherence. Referring to the INCOMIN and EVIDENCE trials, tolerability and adverse events were similar between the three different interferons. However, injection-site reactions occurred more frequently with Betaferon in INCOMIN (37%) and with Rebif in EVIDENCE (81%), both compared with Avonex (8 and 25%, respectively). Furthermore, the similarities in adverse event data from the INCOMIN and EVIDENCE studies between high-dose, high-frequency therapies and glatiramer acetate or interferon beta-1a indicate that tolerability is not sacrificed for greater efficacy (see Figure 5).

The Betaferon versus RebiF Investigating Higher Tolerability (BRIGHT) study was a non-randomised prospective observational study specifically designed to compare injection-site pain and reactions in relapsing–remitting MS (RRMS) patients treated with either Betaferon or RebiF, with a subgroup analysis that explored the relationship between needle gauge and injection pain. Regardless of whether pain was assessed immediately or 30 or 60 minutes after the injections, a significantly higher proportion of patients treated with Betaferon experienced pain-free injections compared with patients receiving RebiF. The smaller needle gauges used by Betaferon patients were associated with less discomfort as well and, according to the speaker, could potentially lead to increased adherence.

An assessment of the BEYOND study showed a trend towards greater adherence with 250mcg interferon beta compared with glatiramer acetate. When analysing the profile of the adverse effects, injection-site reactions demonstrated a significant advantage in favour of interferon beta-1b 250mcg in comparison with glatiramer acetate, largely in the incidence of injection-site pain and injection-site pruritus. Furthermore, lipoatrophy was observed only in patients who received glatiramer acetate (see Figure 5). Systemic reactions such as dyspnoea, chest pain, flushing and chest discomfort were also significantly lower in interferon-treated patients than in those who received glatiramer acetate. Reports of flu-like symptoms were more prominent in patients receiving interferon beta-1b, but the incidence decreased with time in all treatment arms.

However, the issue remains of how patient adherence can be promoted. Dr Baum emphasised the fact that therapies will work only in patients who take them and, expressing a need for specialised MS nurses, presented the Betaferon Education Training and Assistance (BETA) nurse programme. This programme provides a physician’s clinic with a dedicated BETA nurse, and is the only MS nurse programme with around-the-clock availability to provide free training kits, auto-injectors and sharps containers. The nurses also offer ongoing support tailored to the patient’s needs, as well as access to educational events and materials, and provide personalised one-on-one injection training, in an in-home situation if the patient so wishes. In doing so, the trained nurses can identify any MS symptoms and manage any adverse events of treatment, helping to promote patient adherence and reduce decline into poor quality of life. By monitoring patients in such a way, the nurses also have the opportunity to notice any change in the patient and report back to the neurologist with updates regarding patient treatment and compliance. The MS nurse therefore plays a central role in the long-term treatment of MS patients, covering a number of potential factors relevant for increased treatment adherence.

Does it work, though? A large-scale analysis examining the adherence of over 4,000 patients enrolled in the BETA nurse programme in the US saw high rates in favour of the patients who had contact with a BETA nurse compared with the historical cohort who did not after 13 months (88 versus 63%) (see Figure 6). The new Betaferon prospective study on Adherence, Coping and Nurse support (BEACON) study is an international, multicentre, non-interventional study that centres on MS nurse activities and their influence on adherence, and aims to increase knowledge about early treatment cessation, the reasons for doing so and predictive factors.
Multiple Sclerosis

An Emergence of Oral Therapies

Considering that all currently available therapies for multiple sclerosis (MS) require regular parenteral administration, oral therapies are indeed a step forward in drug development. Several are in phase III clinical trials – laquinimod, fingolimod (FTY-720), teriflunomide, demethyl fumarate (DMF; BG12) and oral cladribine, to name a few – and with the exception of oral cladribine, which has a short-course intermittent dosing regimen, these drugs require a daily or several-times-daily dosing regimen (see Table 2). Most of these aforementioned molecules have origins in oncology or transplantation. In two separate satellite symposium proceedings, Drs Patrick Vermersch (France) and Robert Fox (US) presented recent evidence in support of oral cladribine and BG12, respectively, in the treatment of MS.

Clinical and magnetic resonance imaging (MRI) data from a number of previous trials with parenteral cladribine have shown promise for the synthetic purine nucleoside analogue in treating MS.89–92 Parenteral cladribine increased the proportion of relapse-free relapsing–remitting MS (RRMS) patients and reduced the relapse rate, while also reducing the percentage of patients with Gd+ T1-lesions and suppressing Gd+ T1-lesion volume. Parenteral cladribine also has a favourable safety profile, and was generally well tolerated by patients, with dose-related adverse events more frequent at higher doses of cladribine (≥2.8mg/kg); however, such high doses are not used in MS. Cladribine tablets are unique in that they offer a convenient short-course dosing regimen: once daily for five days per course for a total of 10 or 20 days per year of treatment.93 This, compared with other oral MS therapies that require daily administration, has been proposed to improve adherence to therapy.94

The Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study is an ongoing study over a two-year period. Over the first year of treatment, patients with relapsing MS are randomised into one of three arms to receive: four courses of oral cladribine; two courses of oral cladribine followed by two courses of placebo; or four courses of placebo. In the second year, the placebo arm continued to receive placebo, while the active treatment groups received two courses of oral cladribine. The primary end-point is relapse rate. Secondary objectives include the clinical end-points disability progression, MRI parameters and safety assessments.95 A two-year extension study has since been designed to evaluate the safety of extended treatment of patients who complete the CLARITY study, as well as the long-term effects of cladribine tablets, the effect on immunological parameters and gene expression profiles, quality of life and socioeconomic measures. According to Dr Vermersch, efficacy data on the CLARITY trial are expected in 2009.

Even though BG12 was originally approved for the treatment of psoriasis vulgaris, its mechanism of action provides a rationale for its use in MS. Animal models of brain inflammation have shown that BG12 improves clinical scores and decreases inflammation by stabilising axons and myelin.96,97 Furthermore, BG12 has demonstrated ability in activating the Nrf2 pathway in cellular defence against toxic, metabolic and inflammatory stresses.98 In a phase II clinical study treating RRMS patients with BG12, patients experienced significant reductions in new Gd+ lesions, T2 lesions and T1 black holes.99 Currently, there are two ongoing phase III BG12 clinical studies: Determination of the Efficacy and Safety of Oral Fumarate in Relapsing–Remitting MS (DEFINE) and Comparator and an Oral Fumarate In Relapsing-remitting Multiple Sclerosis (CONFIRM). It is hoped that these studies will help further define the efficacy and safety of oral BG12 in patients with relapsing MS.

### Table 2: Oral Therapies in Development for Multiple Sclerosis

<table>
<thead>
<tr>
<th>Agent</th>
<th>Treatment Target</th>
<th>History</th>
<th>Dosing Regimen</th>
<th>Development Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>BG12</td>
<td>Prevention of T-cell activation</td>
<td>Derivative of fumaric acid</td>
<td>Several times daily</td>
<td>III</td>
</tr>
<tr>
<td>Cladribine</td>
<td>Preferential lymphocyte depletion</td>
<td>Approved for hairy cell leukemia and lymphoma</td>
<td>Short-course regimen</td>
<td>III</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>Lymphocyte trafficking</td>
<td>Failed phase III trials for prevention of renal allograft rejection</td>
<td>Daily</td>
<td>III</td>
</tr>
<tr>
<td>Laquinimod</td>
<td>Prevention of T-cell activation</td>
<td>Derived from roquinimex, originally developed for oncology</td>
<td>Daily</td>
<td>III</td>
</tr>
<tr>
<td>Teriflunomide</td>
<td>Lymphocyte antiproliferation</td>
<td>Active metabolite of methotrexate arthritis drug leflunomide</td>
<td>Daily</td>
<td>III</td>
</tr>
</tbody>
</table>

Drug Deliverance – Bringing New Developments to the Table

Given the various presentations on new drugs for treating MS at the ENS, many new therapies are anticipated for the future, some of which may be available as early as next year. Among these new developments is the recombinant T-cell receptor ligand RTL1000, which, according to the phase I safety study update, has so far completed two of five planned cohorts assessing safety in escalating intravenous doses, and enrolment for this study is continuing.104 The first human-dose study of PI-2301, a second-generation peptide copolymer with a mechanism of action similar to that of glatiramer acetate, found the investigational drug to be generally well tolerated among the 56 healthy male volunteers enrolled; further data collection and analyses are under way and are expected to be available by the end of 2008.105

---

**symposium proceedings, Dr Kieseier showed that disability – not just physical disability but cognition as well – impairs quality of life in the patient; a higher EDSS score can be argued to present with a lower quality of life.102 Many studies have shown that traditional disease-modifying treatment can have a positive effect on more than just disability and relapse rate, and can indeed improve patient quality of life compared with the baseline quality of life assessment over time as well.103–107**
A retrospective double-blind analysis of the MRI data collected from the first year of the two-year phase II clinical trial of MN-166 (budilast, MediciNova Inc.) in relapsing MS patients has suggested the drug’s ability to protect neurons from persistent damage following the formation of acute lesions, preventing conversion to persistent black holes; the presenters noted that further studies regarding black hole formation and disease progression in patients with relapsing or progressive MS are warranted. The CD52-specific monoclonal antibody alemtuzumab (Bayer/Genzyme), which targets lymphocytes, has been compared with high-dose interferon beta-1a (Rebif) in the phase II CAMMS223 study treating patients with RRMS. The study showed that at the three-year follow-up the antibody was more effective at suppressing relapses and disability in patients than the interferon, with patients in the former group experiencing a 73% reduction in risk of relapse (p<0.0001) and a 70% reduction in risk of sustained accumulation of disability (p<0.0001). Subgroup analyses found the treatment effects of alemtuzumab to be consistent across age, sex, race and country, indicating that these findings were independent of patient baseline demographics.

Some of these drugs being developed and studied are oral compounds – a class of MS therapies that is amassing increasing interest from researchers and physicians alike. One example of these new oral drugs is laquinimod (Teva Pharmaceutical), MRI data from an extension of the double-blind, randomised, placebo-controlled phase IIb study have shown that patients benefited in terms of reductions in the mean number of T1 lesions when switching to laquinimod from placebo, although no significant difference in annualised relapse rate could be discerned.

Summary
The revelations in MS at the 18th meeting of the ENS have shown a great deal of evidence arguing in support of early treatment, endeavouring to protect patients against disease progression and further deterioration of the CNS. Recent research suggests an increase in the prevalence of the disease, which makes it all the more important to establish an optimal therapy. Many recommendations and even more options exist as to selecting a drug for a patient, and many factors must be considered before choosing to start a patient on any given treatment. Experts in the field have placed heavy emphasis on the benefits of early treatment, when patients can experience greater drug efficacy than at any other phase of the disease course. Many recent drug trials have demonstrated a move towards greater safety and tolerability, while maintaining a high level of efficacy. Therapies are only as effective as the adherence, and programmes providing personal assistance and monitoring have proved successful in upholding a high level of adherence among patients. Many new drugs are in development as well; of these, there is great anticipation for the oral therapies being tested, where it is hoped that the new advantage of convenience over the current parenteral options will also help to maintain good adherence levels.
42. Flaim V, Baulac J, Jacobs J, et al., Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis, J Neurol, 2005;253:1160–64.
44. Khan O, Perumal J, Heiba S, et al., Immune suppression as the initial disease-modifying therapy in clinically active relapsing MS, J Neurol, 2008;255(Suppl. 2):P243.
47. Biogen Idec and Elan Celebrate Second Anniversary of Tysabri® for the Treatment of Multiple Sclerosis. Available at: www.biogenidec.com/news-and-media.html?id_.